- ROUNDTABLE: Pharmacy’s future in sync with technology
- FDA sets advisory committee meeting for potential switch of Merck's Singulair Allergy tablets
- CFC inhalers to be phased out by end of year, FDA says
- FDA advisory committee to consider OTC NDA for asthma-relieving Primatene HFA
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
HYDERABAD, India — Dr. Reddy's Labs has launched a generic drug for treating asthma and allergies, and preventing bronchospasm during exercise, the company said.
The Indian company announced the launch of montelukast sodium oral granules in the 4-mg strength in unit-dose cartons of 30 packets.
The drug is a version of Merck's Singulair oral granules, which had sales of about $61 million during the 12-month period ended in July, according to IMS Health.